Status:
UNKNOWN
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Lead Sponsor:
China National Center for Cardiovascular Diseases
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-79 years
Brief Summary
Recent evidences have demonstrated improved diagnostic accuracy for detecting coronary artery disease (CAD) when myocardial blood flow (MBF) is quantified in absolute terms using single photon emissio...
Eligibility Criteria
Inclusion
- Age 18 \~ 79 years old
- At least one CAD risk factor
- Intermediate to high pre-test likelihood for CAD
- Suspected or known CAD, clinically referred for invasive coronary angiography
- Able and willing to comply with the study procedures
- Written informed consent
Exclusion
- History or risk of severe bradycardia
- History of myocardial infarction, dilated cardiomyopathy, hypertrophic cardiomyopathy, valve issue or congenital heart disease
- Wheezing asthma or COPD
- Known second- or third-degree AV block
- Known hypersensitivity to dipyridamole or adenosine
- Known coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) prior to screening
- Breastfeeding or pregnancy
- Claustrophobia or inability to lie still in a supine position
- Unwillingness or inability to provide informed consent
Key Trial Info
Start Date :
September 9 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT06030596
Start Date
September 9 2022
End Date
December 1 2023
Last Update
September 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai Hospital
Beijing, Beijing Municipality, China, 100037